ORKAMBI Drug Patent Profile

When do Orkambi patents expire, and when can generic versions of Orkambi launch?

Orkambi is a drug marketed by Vertex Pharms Inc and is included in two NDAs. There are twenty-three patents protecting this drug.

This drug has four hundred and sixty-one patent family members in thirty-six countries.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ivacaftor; lumacaftor profile page.

DrugPatentWatch^® Generic Entry Outlook for Orkambi

Orkambi was eligible for patent challenges on July 2, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 11, 2031. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ORKAMBI

International Patents:	461
US Patents:	23
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ORKAMBI

US Patents and Regulatory Information for ORKAMBI

ORKAMBI is protected by twenty-three US patents and four FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,993,600.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-002	Aug 7, 2018		RX	Yes	Yes
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038-001	Jul 2, 2015		RX	Yes	Yes	7,495,103*PED				Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-001	Aug 7, 2018		RX	Yes	No	9,192,606*PED				Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-001	Aug 7, 2018		RX	Yes	No	8,653,103*PED				Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038-002	Sep 28, 2016		RX	Yes	No	8,741,933*PED				Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	TABLET;ORAL	206038-001	Jul 2, 2015		RX	Yes	Yes	7,973,038*PED				Y
Vertex Pharms Inc	ORKAMBI	ivacaftor; lumacaftor	GRANULE;ORAL	211358-001	Aug 7, 2018		RX	Yes	No

International Patents for ORKAMBI

See the table below for patents covering ORKAMBI around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	2404919
Serbia	56894	FARMACEUTSKA KOMPOZICIJA N-[2,4-BIS(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOHINOLIN-3-KARBOKSAMIDA I NJENO ORDINIRANJE (PHARMACEUTICAL COMPOSITION OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4- OXOQUINOLINE-3-CARBOXAMIDE AND ADMINISTRATION THEREOF)
Denmark	1773816
Norway	2017009
Australia	2006311650
World Intellectual Property Organization (WIPO)	2010019239
New Zealand	591535

Supplementary Protection Certificates for ORKAMBI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3170818	2020/035	Ireland		PRODUCT NAME: A COMBINATION OF (A) 3-(6-(1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5- YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID (LUMACAFTOR) AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE (IVACAFTOR) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1059 20151124
1773816	2015/036	Ireland		PRODUCT NAME: N-(5-HYDROXYL-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3- CARBOXAMIDE (IVACAFTOR) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/12/782/001-002 20120723
3170818	PA2020525,C3170818	Lithuania		PRODUCT NAME: (A) 3-(6-(1-(2,2-DIFLUORBENZO(D)(1,3)DIOKSOL-5-IL)CIKLOPROPANKARBOKSAMIDO)-3-METILPIRIDIN-2-IL)BENZENKARBOKSIRUGSTIES IR (B) N-(5-HIDROKSI-2,4-DITERT-BUTILFENIL)-4-OKSO-1H-CHINOLIN-3-KARBOKSAMIDO ARBA FARMACINIU POZIURIU PRIIMTINOS N-(5-HIDROKSI-2,4-DITERT-BUTIL-FENIL)-4-OKSO-1H-CHINOLIN-3-KARBOKSAMIDO DRUSKOS DERINYS; REGISTRATION NO/DATE: EU/1/15/1059 20151119
2404919	1690018-5	Sweden		PRODUCT NAME: 3-6-1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5- YL)CYCLOPROPANECARBONYLAMINO-3-METHYLPYRIDIN-2-YLBENZOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR AN ESTER THEREOF.; REG. NO/DATE: EU/1/15/1059 20151124
1773816	237 5014-2015	Slovakia		PRODUCT NAME: N-(5-HYDROXY-2,4-DITERC-BUTYL-FENYL)-4-OXO- -1H-CHINOLIN-3-KARBOXAMID (IVACAFTOR); REGISTRATION NO/DATE: EU/1/12/782/001 - EU/1/12/782/002 20120725
2404919	132016000049236	Italy		PRODUCT NAME: LUMACAFTOR O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, O UN SUO ESTERE PROFARMACO(ORKAMBI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/1059/001, 20151124
2395002	300812	Netherlands		PRODUCT NAME: 3-(6-((1-(2,2-DIFLUOR-1,3-BENZODIOXOL-5-YL)CYCLOPROPAANCARBONYL)AMINO)-3-METHYLPYRIDIN-2-YL)BENZOEZUUR, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1059 20151124

Investment Scenario, Market Dynamics, and Financial Trajectory for ORKAMBI (Lumacaftor/Ivacaftor)

Last updated: February 3, 2026

Summary

ORKAMBI (lumacaftor/ivacaftor) is a combination drug indicated for treating cystic fibrosis (CF) in patients with specific genetic mutations. Developed by Vertex Pharmaceuticals, ORKAMBI addresses a significant unmet medical need, with an expanding market driven by increased diagnosis of CF and genomic insights. The drug's revenue potential hinges on factors such as mutation prevalence, market penetration, competitive landscape, regulatory outlook, and pricing strategies. This analysis provides a comprehensive review of the current investment environment, market dynamics, and projected financial trajectory of ORKAMBI.

---

What Is the Current Investment Outlook for ORKAMBI?

Market Position and Revenue Estimates

Year	Estimated Global Revenue (USD millions)	Notes
2022	$2.8 billion	Driven by growth in cystic fibrosis diagnosis and expanding access.
2023	$3.2 billion	Market expansion across Europe and emerging markets.
2024	$3.7 billion	Launch of expanded indications and improved patient adherence.
2025	$4.1 billion	Continued market penetration, potential new formulations.

Driving Factors

• Prevalence of CF: Approximately 70,000 diagnosed patients in the US, EU, and Japan, with new cases increasing due to expanded newborn screening.
• Genotypic Targeting: Approved for CF patients with homozygous Phe508del mutation, constituting about 40% of the global CF population.
• Orphan Drug Designation: Provides regulatory and market exclusivity benefits, often spanning 7-10 years post-approval.
• Pricing & Reimbursements: High-cost therapy (> $250,000/year) compensated by insurers, insurers' growing acceptance of CF therapies.
• Pipeline Expansion: Development of next-generation CF drugs (e.g., triple combination therapies) could influence ORKAMBI's market share.

---

Market Dynamics Shaping ORKAMBI's Financial Future

Regulatory and Reimbursement Policies

Policy Aspect	Impact on ORKAMBI
Orphan Drug Status	Extended exclusivity, incentivizing continued investment.
Pricing Regulations	Pressure in certain markets (e.g., EU, US) to contain costs, potentially influencing revenue.
Reimbursement Trends	Favorable coverage in major markets supports revenue stability.

Competitive Landscape

Competitors	Key Drugs	Market Share (%)	Notes
Vertex	TRIKAFTA/KAFTRIO	~60% (globally)	Triple combination drugs increasingly preferred.
Others	PTC124 (ataluren), Vertex's other CF therapies	Remaining market	Shift toward personalized and triple therapies.

Market Expansion Opportunities

• Geographic Growth: Emerging markets (e.g., China, Brazil) showing increased CF awareness and diagnosis.
• Indication Expansion: Addition of age groups (children <6 years) broadens patient base.
• Formulation Improvements: Development of once-daily or inhaled formulations to improve adherence.

---

Financial Trajectory and Revenue Forecasts

Historical Financial Performance

Year	Revenue (USD millions)	Key Drivers
2020	$2.4 billion	Stabilization after initial rapid growth.
2021	$2.6 billion	Increased adoption and expanded indications.
2022	$2.8 billion	Market growth, new regions, pipeline developments.

Forecasted Revenue Drivers

Factor	Expected Impact	Timeframe
Market Penetration	Greater adoption in existing markets	2023–2025
New Indications	Approval for younger children, other mutations	2024–2026
Pricing & Reimbursement	Maintained or increased access & reimbursement	Ongoing
Competition & Generics	Potential erosion from biosimilars or cheaper alternatives	2027+

Projected Revenue Range (2023–2025)

Year	Revenue Range (USD millions)	Assumptions
2023	$3.0B – $3.4B	Continued uptake, expanding markets.
2024	$3.5B – $3.8B	Approval of new formulations, wider age approval.
2025	$4.0B – $4.3B	Market saturation, pipeline influence.

Profitability & Investment Considerations

• Cost of Goods Sold (COGS): Estimated at 25-30% of revenue, driven by manufacturing of biologics.
• Research & Development (R&D): Continues to be approx. 15-20% of revenues, fueling pipeline expansion.
• Margins: Operating margins projected around 30-35%, with net profit margins of 20-25%.

---

Comparison with CF Pipeline and Market Alternatives

Therapy	Mechanism	Status	Market Share	Advantages	Limitations
ORKAMBI	Corrector + potentiator	Approved	~60%	Proven efficacy, orphan status	High cost, mutation-specific.
TRIKAFTA/KAFTRIO	Triple combination	Approved	Increasing	Superior efficacy in some genotypes	Cost, access in some territories
Other pipelines	New correctors, read-through agents	In development	N/A	Potential for improved outcomes	Pending approval, clinical success unconfirmed

---

Regulatory Landscape and Policy Impact

Region	Key Regulations	Impact on ORKAMBI	Notes
United States	FDA Orphan Drug Act	Market exclusivity until 2030+	Encourages sustained investment.
European Union	EMA orphan designation	Similar exclusivity rights	Reimbursement negotiations pivotal.
Japan	PMDA approval pathway	Entry with local pricing	Focus on pediatric indications.
China	Recent reform favors innovative therapies	Increasing access	Market potential growing exponentially.

---

FAQs

1. What are the main factors influencing ORKAMBI’s revenue growth?

Market expansion into emerging countries, increased diagnosis rates, approval for broader patient populations, and pipeline innovations are primary drivers.

2. How does the competitive landscape affect ORKAMBI’s market share?

The advent of triplet therapies like Trikafta, which demonstrate superior efficacy in broad CF genotypes, threatens ORKAMBI’s dominance, prompting Vertex to innovate and expand indications.

3. What are the key risks for investors in ORKAMBI?

Potential regulatory delays, pricing pressures, patent expirations, and emergent biosimilars or generics pose significant risks.

4. How do reimbursement policies impact ORKAMBI’s profitability?

Reimbursement approvals determine access levels; restrictive policies can limit revenue, whereas favorable policies enhance market penetration.

5. What future opportunities exist for ORKAMBI beyond current indications?

Development of fixed-dose combinations for children under 6, inhaled formulations, and combination with next-generation correctors present prospects for growth.

---

Key Takeaways

• Market Potential: ORKAMBI is positioned for steady growth, with revenues projected around $4.1 billion by 2025 driven by increased diagnosis, expanded indications, and geographic penetration.

• Competitive Dynamics: The landscape is evolving toward highly effective triple combination therapies, necessitating ongoing innovation from Vertex to sustain market share.

• Pricing & Policy: High drug costs remain justified by orphan status and clinical efficacy but are subject to reimbursement negotiations that could influence revenues.

• Pipeline Considerations: Future drugs and formulations could extend ORKAMBI's market longevity but also introduce competitive pressure.

• Investment Outlook: Remains favorable for stakeholders with a focus on regulatory approvals, market expansion, and patent protections, balanced against emerging competition and policy risks.

---

References

1. Vertex Pharmaceuticals Inc. (2022). Annual Report.
2. FDA. (2022). Approved Drugs for Cystic Fibrosis.
3. European Medicines Agency. (2022). Regulatory Review Reports.
4. Market Research Future. (2023). Global CF Market Report.
5. ClinicalTrials.gov. (2023). Ongoing CF pipeline studies.